Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 47, pseudogene (RNU6-47P) is classified as a **pseudogene** relating to the U6 small nuclear RNA (snRNA) family, which is normally an integral component of the spliceosome complex responsible for pre-mRNA splicing[1][2][3][5]. Pseudogenes such as RNU6-47P usually arise via mechanisms like retrotransposition or genomic duplication but accumulate mutations that render them non-functional and typically **not transcribed into functional RNA or protein** products[1]. The canonical, functional U6 snRNA itself is essential for splicing, forming part of the catalytic core of the spliceosome[3][5]. By contrast, the RNU6-47P locus is considered **non-functional** and does not participate in splicing or any other known cellular process. There are no current data associating this pseudogene with disease, drug interactions, or use as a biomarker. Thus, RNU6-47P is *not* considered a therapeutic drug target, receptor, enzyme, transporter, or otherwise active biomolecule in human biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 47, pseudogene (RNU6-47P).